Spots Global Cancer Trial Database for First in Human, Dose Escalation, Dose Expansion Study of AUR105
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First in Human, Dose Escalation, Dose Expansion Study of AUR105
Official Title: A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR105 in Patients With Relapsed Advanced Malignancies (SURYA-1)
Study ID: NCT05605119
Interventions
Study Description
Brief Summary: This is a multi-center, open-label, First in Human, Phase 1 study of AUR 105 in adult patients with advanced malignancies. The study will have two parts: a Dose Escalation Part and Dose Expansion Part.
Detailed Description: This is a Phase I, Open label First in Human Study in adult patients with relapsed advanced malignancies. The study will have two parts. Dose escalation part and Dose expansion part
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HCG City Cancer Center, Vijayawada, Andhra Pradesh, India
Omega Hospitals, Visakhapatnam, Andhra Pradesh, India
Kailash Cancer Hospital and Research Centre, Vadodara, Gujarat, India
Moraya Multi-Speciality Hospital, Pune, Maharasthra, India
Krupamayi Hospital, Aurangabad, Maharastra, India
Sparsh Hospital and Critical Care, Bhubaneswar, Odisha, India
All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
IMS&SUM Hospital, Bhubaneswar, , India
ALL India Institute of medical Scieneces, New Delhi, , India
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
